登录 添加会员 求助
 
JinanJianfengChemicalCo.,Ltd.
 
 
Recommended Results 
 
Apixaban intermeidate Cas 545445-44-1 

  产品分类 : 化學->活性醫療成份

     
Apixaban intermeidate Cas 545445-44-1
         

  产品规格
 
  Country  CN

 

  产品描述
   
  <p class="MsoNormal">
Chemical&nbsp;Name: 3-Morpholino-1-(4-(2-oxopiperidin-1-yl)phenyl)-5,6-dihydropyridin-2(1H)-one
</p>
<p class="MsoNormal">
Molecular&nbsp;Formula: C20H25N3O3<br />
Formula&nbsp;Weight: 355<br />
CAS&nbsp;No.: 545445-44-1
</p>
<p class="MsoNormal">
<img src="http://i.bosscdn.com/product/e0/26/d3/df60537fa57cd5a64a040e3808.gif" title="545445-44-1" alt="545445-44-1" /><br />
An&nbsp;alternate&nbsp;approach&nbsp;to&nbsp;apixaban&nbsp;was&nbsp;described.&nbsp;The&nbsp;synthesis&nbsp;features&nbsp;a&nbsp;novel&nbsp;and&nbsp;cost-effective&nbsp;synthetic&nbsp;strategy&nbsp;to&nbsp;construct&nbsp;a&nbsp;key&nbsp;N-phenylvalerolactam&nbsp;intermediate&nbsp;4&nbsp;from&nbsp;4-nitroaniline.&nbsp;In&nbsp;addition,&nbsp;the&nbsp;modifiedStroke Prophylaxis with Atrial Fibrillation<br />
Indicated to reduce risk of stroke and systemic embolism associated with nonvalvular atrial fibrillation<br />
<br />
5 mg PO BID<br />
<br />
Postoperative Prophylaxis of DVT/PE<br />
Indicated following hip or knee replacement surgery<br />
<br />
Initial: Give 2.5 mg PO 12-24 hr after surgery<br />
<br />
Duration of therapy (hip replacement): 2.5 mg PO BID for 35 days<br />
<br />
Duration of therapy (knee replacement): 2.5 mg PO BID for 12 days<br />
<br />
Renal impairment, including with ESRD on dialysis<br />
<br />
Deep Vein Thrombosis: No dose adjustment recommended; clinical efficacy and safety studies did not enroll patients with ESRD on dialysis or patients with a CrCl &lt;15 mL/min; dosing recommendations are based on pharmacokinetic and pharmacodynamic (anti-FXa activity) data in study subjects with ESRD maintained on dialysis<br />
&nbsp;synthetic&nbsp;route&nbsp;avoids&nbsp;the&nbsp;use&nbsp;of&nbsp;expensive&nbsp;reagents&nbsp;and&nbsp;significantly&nbsp;improves&nbsp;reaction&nbsp;yields.&nbsp;As&nbsp;demonstrated&nbsp;practically,&nbsp;apixaban&nbsp;was&nbsp;successfully&nbsp;synthesized&nbsp;in&nbsp;overall&nbsp;good&nbsp;yield&nbsp;(35%).
</p>
<p class="MsoNormal">
<br />
</p>pharmachemm.com

  其他类似产品
 
Ozenoxacin intermediate cas 103877-51-6

Ozenoxacin intermediate cas 103877-51-6
Tadanafil intermediate cas 171489-59-1 Chloropretadalafil

Tadanafil intermediate cas 171489-59-1 Chloropretadalafil
lurasidone intermediate cas 186204-35-3

lurasidone intermediate cas 186204-35-3
Iguratimod intermediate cas 149436-41-9 cas 149457-03-4

Iguratimod intermediate cas 149436-41-9 cas 149457-03-4
 
   


[ 返回产品型录 ]

Commerce 会员:
请登录您的帐号跟口令,系统将为您填入您的相关资料
 
 
帐号:
口令:
 记住我的帐号
 
 
填写下列表格并寄送询问函．所有的询问信函将会自动寄发给你想联络的公司
主題
內容 （ 请勿输入公司名称、Email、电话、传真、网址 ）
   

 


公司简介:
* 公司名称
*E-mail
*国家
*联络人
网址
*电话
 - -
传真
 - -
*邮递区号
*城市
*街道地址
*企业形态
 批发商   出口商 进口商 制造商
大盘商 零售商  代理商 Retrofitter 使用者
其他, 请详细说明:
*安全口令
请输入所显示的安全口令


网站导览 l 隐私权政策 l 服务团队 l 合作提案 l 联络我们 l 帮帮我 l 广告刊登l  B2B商业伙伴
    .